×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ESPR – esperion therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ESPR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/26
06:43 am
espr
Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Medium
Report
Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
11/25
09:19 am
espr
Esperion Therapeutics (NASDAQ:ESPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.
High
Report
Esperion Therapeutics (NASDAQ:ESPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.
11/25
09:16 am
espr
Why Analysts Are Rewriting Esperion's Story After New Pipeline Results and Global Partnerships [Yahoo! Finance]
Low
Report
Why Analysts Are Rewriting Esperion's Story After New Pipeline Results and Global Partnerships [Yahoo! Finance]
11/21
08:00 am
espr
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Medium
Report
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
11/19
08:00 am
espr
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
Low
Report
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
11/18
08:01 am
espr
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease [Yahoo! Finance]
Low
Report
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease [Yahoo! Finance]
11/18
07:00 am
espr
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
Low
Report
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
11/12
09:07 am
espr
Esperion Therapeutics (NASDAQ:ESPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Esperion Therapeutics (NASDAQ:ESPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
06:00 am
ESPR
esperion therapeutics, inc.
MISS
Report
-4.2%
esperion therapeutics, inc.
8/5/2025
06:00 am
ESPR
esperion therapeutics, inc.
BEAT
Report
-0.6%
esperion therapeutics, inc.
5/6/2025
06:00 am
ESPR
esperion therapeutics, inc.
MISS
Report
-5.3%
esperion therapeutics, inc.
3/4/2025
06:00 am
ESPR
esperion therapeutics, inc.
BEAT
Report
12.0%
esperion therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/17
04:09 pm
espr
Form 3 Esperion Therapeutics, For: Nov 17 Filed by: Harlow John B. Jr.
Low
Report
Form 3 Esperion Therapeutics, For: Nov 17 Filed by: Harlow John B. Jr.
11/14
11:44 am
espr
Form SCHEDULE 13G/A Esperion Therapeutics, Filed by: Two Seas Capital LP
Low
Report
Form SCHEDULE 13G/A Esperion Therapeutics, Filed by: Two Seas Capital LP
11/12
03:32 pm
espr
Form SCHEDULE 13G/A Esperion Therapeutics, Filed by: WASATCH ADVISORS LP
Medium
Report
Form SCHEDULE 13G/A Esperion Therapeutics, Filed by: WASATCH ADVISORS LP
11/6
04:13 pm
espr
Form 10-Q Esperion Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Esperion Therapeutics, For: Sep 30
11/6
07:32 am
espr
Form 8-K Esperion Therapeutics, For: Nov 06
Medium
Report
Form 8-K Esperion Therapeutics, For: Nov 06
11/4
08:50 am
espr
Form 8-K Esperion Therapeutics, For: Nov 04
Low
Report
Form 8-K Esperion Therapeutics, For: Nov 04
10/20
06:49 pm
espr
Form 4 Esperion Therapeutics, For: Oct 17 Filed by: Looker Benjamin
Low
Report
Form 4 Esperion Therapeutics, For: Oct 17 Filed by: Looker Benjamin
10/17
03:14 pm
espr
Form 144 Esperion Therapeutics, Filed by: Looker Benjamin
Low
Report
Form 144 Esperion Therapeutics, Filed by: Looker Benjamin
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
Form 8-K Esperion Therapeutics, For: Mar 14
18.2%
3/17 Esperion Therapeutics Inc (NASDAQ: ESPR) was upgraded by analysts at Citigroup Inc from a "neutral" rating to a "buy" rating. 14.6%
5/5 Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review 11.6%
11/17 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions 10.0%
4/20 Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan 7.2%
1/31 Form 8-K Esperion Therapeutics, For: Jan 31 6.6%
2/12 Form SC 13G/A Esperion Therapeutics, Filed by: VANGUARD GROUP INC 5.9%
2/28 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 5.2%
4/16 Form DEF 14A Esperion Therapeutics, For: May 28 4.6%
3/23 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiol 4.5%
3/17 Esperion Therapeutics Inc (NASDAQ: ESPR) was upgraded by analysts at Citigroup Inc from a "neutral" rating to a "buy" rating. 14.6%
5/5 Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review 11.6%
11/17 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions 10.0%
4/20 Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan 7.2%
1/31 Form 8-K Esperion Therapeutics, For: Jan 31 6.6%
2/12 Form SC 13G/A Esperion Therapeutics, Filed by: VANGUARD GROUP INC 5.9%
2/28 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 5.2%
4/16 Form DEF 14A Esperion Therapeutics, For: May 28 4.6%
3/23 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiol 4.5%
TOP News Decliners
2/27
Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results
-11.2%
3/12 Form 4 Esperion Therapeutics, For: Mar 11 Filed by: MAYLEBEN TIMOTHY M -10.3%
4/1 Esperion Therapeutics Inc (NASDAQ: ESPR) is now covered by analysts at Bank of America Corp. They set a "buy" rating and a price target on the stock. -9.3%
11/6 Q3/2019 9/30/2019 EPS -2.520 ZacksConsensus -2.010 ActVsEst (0.510) - Miss -8.6%
3/31 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.9%
4/30 Esperion to Report First Quarter 2020 Financial Results May 6, 2020 -7.9%
1/24 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.3%
2/25 Esperion Therapeutics: The Path After FDA Approval [Seeking Alpha] -4.8%
8/30 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -4.7%
2/14 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. -4.5%
3/12 Form 4 Esperion Therapeutics, For: Mar 11 Filed by: MAYLEBEN TIMOTHY M -10.3%
4/1 Esperion Therapeutics Inc (NASDAQ: ESPR) is now covered by analysts at Bank of America Corp. They set a "buy" rating and a price target on the stock. -9.3%
11/6 Q3/2019 9/30/2019 EPS -2.520 ZacksConsensus -2.010 ActVsEst (0.510) - Miss -8.6%
3/31 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.9%
4/30 Esperion to Report First Quarter 2020 Financial Results May 6, 2020 -7.9%
1/24 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.3%
2/25 Esperion Therapeutics: The Path After FDA Approval [Seeking Alpha] -4.8%
8/30 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -4.7%
2/14 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: